In vitro susceptibility of recent Chlamydia trachomatis clinical isolates to the CtHtrA inhibitor JO146.

Publication Type:
Journal Article
Citation:
Microbes and infection / Institut Pasteur, 2015, 17 (11-12), pp. 738 - 744
Issue Date:
2015-11
Full metadata record
Files in This Item:
Filename Description Size
OngClinicalIsolatesFinal MI REvisedCleanselfarchiveing.pdfAccepted Manuscript Version599.85 kB
Adobe PDF
The present study aimed to establish if a previously identified Chlamydia trachomatis HtrA (CtHtrA) inhibitor, JO146, is effective against currently circulating clinical isolates to validate if CtHtrA is a clinically relevant target for future therapeutic development. Inhibition of CtHtrA during the middle of the chlamydial replicative cycle until the completion of the cycle resulted in loss of infectious progeny for six unique clinical isolates representing different serovars. This supports the potential for CtHtrA to be a clinically relevant target for development of new therapeutics and suggests the importance of further investigation of JO146 as a lead compound.
Please use this identifier to cite or link to this item: